Skip to main content

Table 2 Demographic and clinical characteristics of reported Crohn’s disease patients with hepatosplenic T-cell lymphoma (HSTCL)

From: Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma

  Unique cases (n = 37) Cases with insufficient reportinga(n = 9)
Age at HSTCL diagnosis, years n = 36 n = 0
Mean 30 -
Median 26 -
Range 12 to 79 -
Disease duration, years n = 16 n = 0
Mean 10 -
Median 6 -
Range 4 to 35 -
Sex, n (%) n = 36 n = 6
Female 5 (14%) 1 (17%)
Survival, n (%) n = 26 n = 4
Died 24 (92%) 4 (100%)
Survived 2 (8%) 0 (0%)
Physical examination and laboratory abnormalities at time of HSTCL diagnosis, n (%) n = 19 n = 1
Hepatosplenomegaly or splenomegaly 19 (100%) 1 (100%)
Fever 9 (47%) -
Cytopenia of any type 11 (58%) -
Altered liver enzymes and/or LDH 5 (26%) -
  1. aInsufficient reporting on demographic information prevented us from identifying if the cases were unique. With each patient characteristic heading, the adjacent ‘n = x’ cells indicate the number of cases that reported on that particular demographic. The percentages calculated for sex, survival, and physical examination/laboratory abnormalities use this ‘n’ as the denominator. HSTCL, hepatosplenic T-cell lymphoma, LDH, lactate dehydrogenase.